NCT04908709Recruiting
Spectroscopic MRI Guided Proton Therapy in Assessing Metabolic Change in Pediatric Patients With Brain Tumors
Spectroscopic MRI Guided Proton Therapy for Pediatric High-Grade Glioma (RAD4500)
Source: ClinicalTrials.gov · Last updated 4 Mar 2026
Brief summary (registry, in English)
This trial studies how well spectroscopic magnetic resonance imaging (MRI) guided proton therapy works in assessing metabolic change in pediatric patients with brain tumors. The non-invasive imaging, such as spectroscopic MRI may help to map the differences in tumor metabolism compared to healthy tissue without injection of any contrast agent.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 25 (estimated)
- First submitted
- 20 May 2021
- Start date
- 20 Dec 2018
- Primary completion date
- 13 Oct 2029
- Lead sponsor
- Emory University
- Diseases
- Childhood cancers
- NCT number
- NCT04908709
What you commit to
- Study type: Interventional
- Planned participants: 25
- From 20 Dec 2018 to the primary completion date, 13 Oct 2029
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with pacemakers, non-titanium aneurysm clips, neurostimulators, cochlear implants, non-titanium metal in ocular structures, or other incompatible implants which makes MRI safety an issue are excluded.
Other illness
- Patients that have any significant medical illnesses that in the investigator's opinion cannot be adequately tolerate MRI scan are excluded.
Other
- Pathology demonstrated low-grade glioma or other benign or non-invasive brain tumor.
Who the study is looking for
- Pathologically diagnosed high-grade glioma (World Health Organization \[WHO\] grade 3-4). Patients with a radiographically diagnosed high-grade glioma may enroll prior to pathologic confirmation, but would be removed from study if pathology did not confirm the diagnosis of high-grade glioma.
- Primary tumor located within the supratentorial brain.
- Recommended to receive definitive radiation therapy.
- Able to receive MRI scans.
- Both males and females, and members of all races and ethnic groups are eligible for this trial.
Age in the registry: - to 21 years · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Emory University Hospital/Winship Cancer Institute Coordinator of this site? Confirm its status | Atlanta | United States | Recruiting |
| Children's Healthcare of Atlanta, Scottish Rite Coordinator of this site? Confirm its status | Atlanta | United States | Not yet recruiting |
| Emory Proton Therapy Center Coordinator of this site? Confirm its status | Atlanta | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.